Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
American Cancer Society · Fox Chase Cancer Center · +13 more institutions
Abstract
The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)-approved agent for reducing breast cancer risk but did not gain wide acceptance for prevention, largely because it increased endometrial cancer and thromboembolic events. The FDA approved the SERM raloxifene for breast cancer risk reduction following its demonstrated effectiveness in preventing invasive breast cancer in the Study of Tamoxifen and Raloxifene (STAR). Raloxifene caused less toxicity (versus tamoxifen), including reduced thromboembolic events and endometrial cancer. In this report, we present an updated analysis with an 81-month median follow-up. STAR women were randomly assigned to…
Citation impact
- FWCI
- 39.43
- Percentile
- 100%
- References
- 31
Authors
21- VGVictor G. Vogel
American Cancer Society, Fox Chase Cancer Center, The University of Texas MD Anderson Cancer Center, University of Pittsburgh, Allegheny General Hospital, Jewish General Hospital, Kaiser Permanente Vallejo Medical Center, UPMC Hillman Cancer Center, University of Colorado Cancer Center, National Cancer Institute, NSABP Foundation, McGill University, UConn Health, University of Colorado Denver
- JPJoseph P. Costantino
American Cancer Society, Fox Chase Cancer Center, The University of Texas MD Anderson Cancer Center, University of Pittsburgh, Allegheny General Hospital, Jewish General Hospital, Kaiser Permanente Vallejo Medical Center, UPMC Hillman Cancer Center, University of Colorado Cancer Center, National Cancer Institute, NSABP Foundation, McGill University, UConn Health, University of Colorado Denver
- DLD. Lawrence WickerhamCorresponding
American Cancer Society, Fox Chase Cancer Center, The University of Texas MD Anderson Cancer Center, University of Pittsburgh, Allegheny General Hospital, Jewish General Hospital, Kaiser Permanente Vallejo Medical Center, UPMC Hillman Cancer Center, University of Colorado Cancer Center, National Cancer Institute, NSABP Foundation, McGill University, UConn Health, University of Colorado Denver
- WMWalter M. Cronin
American Cancer Society, Fox Chase Cancer Center, The University of Texas MD Anderson Cancer Center, University of Pittsburgh, Allegheny General Hospital, Jewish General Hospital, Southeast Clinical Oncology Research Consortium, Kaiser Permanente Vallejo Medical Center, UPMC Hillman Cancer Center, University of Colorado Cancer Center, National Cancer Institute, NSABP Foundation, McGill University, UConn Health, University of Colorado Denver
- RSReena S. Cecchini
American Cancer Society, Fox Chase Cancer Center, The University of Texas MD Anderson Cancer Center, University of Pittsburgh, Allegheny General Hospital, Jewish General Hospital, Southeast Clinical Oncology Research Consortium, Kaiser Permanente Vallejo Medical Center, UPMC Hillman Cancer Center, University of Colorado Cancer Center, National Cancer Institute, NSABP Foundation, McGill University, UConn Health, University of Colorado Denver
Topics & keywords
- Raloxifene
- Tamoxifen
- Medicine
- Breast cancer
- Selective estrogen receptor modulator
- Endometrial cancer
- Oncology
- Gynecology
- Good health and well-being